We describe methods for studying the binding of Al by protein in serum: ultrafiltration, gel filtration, and immuno-affinity chromatography. For ultrafiltration we used an Amicon YM1 0 cellophane membrane with a nominal cutoff of 10 000 Da to separate ultrafiltrableand non-ultrafiltrableAl. For gel filtrationwe used Sephacryl S-300, and for immuno-affinity chromatographywe used anti-transferrincoupled to CNBr-activated Sepharose to identify the Al-binding protein. For 30 normal subjects 54% of the total Al in serum was nonultrafiltrable; for 30 patients with chronic renal failure being treated by hemodialysis 67% was non-ultrafiltrable. In both groups transfernn was identified as the major Al-binding protein in the serum. Results of gel-filtration studies should be interpretedwithcaution:some gel mediaadsorb"free"Al, whichcan be subsequentlytaken up by transfemnor desferrioxamine passing through the column. We find affinity chromatography to be a specific and reliable method, suitable for use in quantitativestudies. (5), and experimental evidence (6), the exact mechanism by which Al causes these toxic effects is still speculative.
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During hemodialysis, Al transfer occurs against a concentration gradient (7, 8) . The diIcu1ty in removing Al from patients by conventional hemodialysis has led to the belief that Al in serum is largely bound to protein.
Studies of protein binding of Al (9-14) have presented conflicting findings, probably because of the different techniques used. Moreover, many reports involve only a few patients and lack the full explication of experimental details that would allow proper evaluation and interpretation.
We describe techniques for studying the protein binding of Al in serum from normal subjects and from patients with chronic renal failure. Results by ultrafiltration, gel filtration, and immunoaffinity chromatography were reproducible enough for at least qualitative study of protein binding of Al in serum. Results from gel-ifitration experiments suggest that transferrin is responsible for binding much of 
Materials and Methods
We used de-ionized distilled water and "Aristar"-grade nitric acid (BDH Chemicals Ltd., Poole, Dorset, U.K.)
throughout.
Ultrafiltration
Ultrafiltration was done at room temperature in a Model 52 stirred cell (Amicon Ltd., Stonehouse, Gloucestershire, U.K.) fitted with Amicon Diaflo YM1O membranes having a nominal cutoff of 10000 Da. The ultrafiltration cell was pressurized to 5.2 x iO N m2 with COa/air (5/95 by vol). Before use, all components of the ultrafiltration cell were soaked for 24 h in dilute (150 mmol/L) nitric acid, then rinsed in copious amounts of water and air dried. The YM1O membranes were soaked in excess water for at least 1 h, with three changes of water. In each ultrafiltration experiment, 5 mL of sample was pipetted into the filtration cell, the initial five drops of ultrafiltrate were discarded, and the following 1 mL was collected in acid-washed tubes. After each ifitration, the cell and membrane were thoroughly rinsed with water and dried, the ifitration cell being pressurized to remove any water.
When we ultrafiltered 5 mL of distilled water as sample, we found no evidence of Al leaching (initial concentration 3.3 iig/L; concentration in the ultrafiltrate 3 g/L). However, when we ultrafiltered sequentially four aliquots of a serum sample containing 41 g of Al per liter, the ultrafiltrates contained respectively 24, 20, 14, and 14 tg of Al per liter. The reason for the higher Al content of the first two ultrafiltrates was not clear, but it occurred consistently with all the membranes. Thereafter, before using each membrane in the experiment, we ultrafiltered two 5-mL aliquots of a pooled serum sample, to 'prime" the system. Analytical recovery experiments with aqueous Al nitrate solutions (50, 100, and 200 &gfL) showed 96.5 to 99.6% recovery of Al in the ultrafiltrate.
We assessed the intra-batch precision of the system (CV) by ultrafiltering 11 5-mL aliquots of a pooled serum sample; results varied by 3.8%. Repeating this procedure on two consecutive days gave results that varied by 3.9%.
We also carried out ultrafiltration with two hemodialyzers: Dylade 1.3 m2, with Cuprophan#{174} membrane (Dylade Co. Ltd., Runcorn, Cheshire, U.K.) and C-Dak TM 4000,1.4 m2 with Cellulate#{174} membrane (Cordis Dow Corp., Miami Lakes, FL). In both cases the patient's blood was ultrauuitered through the dialyzer at a positive pressure of 2.9 x i0 N m2. The initial 300 mL of ultrafiltrate was discarded and the following 20 mL of ultrafiltrate was collected in acidwashedtubes. Arterial blood collected at the same time was allowed to clot and then centrifuged.
We ultrafiltered the serum, using the Amicon cell. The concentration of ultraf II- 
Gel Filtration
We performed gel ifitration at room temperature with 1.6 x 100 cm columns packed with Sephacryl 5-300 Superfine (Pharmacia Fine Chemicals Ltd., Uppsala, Sweden) and eluted with Earle's Medium: per liter, NaCl 116.4 mmol, KC1 5.4 mmol, CaC12 1.8 mmol, MgSO4 0.4 mmol, NaH2PO4 0.8 mmol, and NaHCO3 26 mmol. We adjusted the pH of the eluting buffer to 7.4 by slowly bubbling C02/air (5/95 by vol) through it. The Al content of the eluting buffer varied from 3 to 5 ug/L.
Before packing, we soaked the column and tubings for 24 h in 3 mol/L nitric acid. The gel was also soaked in nitric acid at pH 4 for a similar period, then rinsed with copious amounts of water. The flow rate of the column under gravity was adjusted to 12 mL/h. We applied 2 mL of serum to the top of the gel bed, collected 90 2-mL fractions in acid-leached tubes, measured the absorbance of each fraction at 280 nm and determined the 1gM, IgG, and transferrin content by ixnmunoturbidimetric assay (see below).
Immunoturbidimetric Assays for lgG, 1gM,and Transferrin
The analytical conditions for the transferrin assay are described below. Those for IgG and 1gM are very similar.
Reagent: Add 400 L of anti-human transfemn (HoechstBehring, Hoechst U.K. Ltd., Hounslow, Middlesex, U.K.) to 11.6 mL of phosphate-buffered saline (pH 7.2) prepared by mixing 40.2 mL of 0.2 mol/L disodium hydrogen phosphate and 9.8 mL of 0.2 mo]JL sodium dihydrogen phosphate and diluting to 1 L with 9 g/L sodium chloride solution containing 40 g of polyethylene glycol 6000 per liter.
Standards:
The concentrations of standards ranged from 5 to 95 mg of human transferrin (Hoechst-Behring) per liter of phosphate-buffered saline.
Procedure:
Immunoturbidimetric analysis was at 25#{176}C, in a Cobas-Bio centrifugal analyzer (Roche Diagnostics, Welwyn Garden City, Herts, U.K.). The sample, diluent, and reagent volumes were 5, 15, and 250 .tL, respectively, and the increase in turbidity was measured 20 and 120 s after mixing.
Immuno-Affinity Chromatography
We prepared an immuno-affInity chromatography column (11 x 0.8 cm, with a bed height of 10cm of gel) from CNBractivated Sepharose 4B and human transferrmn according to the procedure described by Pharmacia Ltd. (15) , using 2 mg of transferrin per gram of dry gel. We applied to the column 6 mL of rabbit anti-human transferrin antiserum diluted threefold in phosphate-buffered isotonic saline (pH 7.2) and collected 9-mL fractions, recycling the first three through the column. We then applied a further 30 mL of phosphatebuffered saline to the column, then eluted the antibody with 0.1 moIJL phosphate citrate buffer, pH 2.8(16). We collected 2-mL fractions and immediately adjusted their pH to 7.0-8.0 with a 2 mol/L solution of Tris buffer. The antibodycontaining fractions, as assessed by absorbance at 280 nm, were pooled and dialyzed for 24 h against 0.1 mol/L bicarbonate buffer containing 0.5 mol of NaC1 per liter. The dialyzed antibody was then coupled to another batch of CNBr-activated Sepharose by a similar procedure and used to prepare a column. Before packing, we soaked this column for 24 h in dilute (150 mmol/L) nitric acid, rinsed with copious amounts of water, then packed the column with the gel medium and passed 30 mL of phosphate-buffered saline through the column to settle the gel. The flow rate of the column was about 12 mL/h. The Al content of the phosphate-buffered saline varied from 2 to 4 tgJL and of the phosphate-citrate buffer from 8 to 9 tg/L. The affinity column had the capacity to bind 1 mg of transferrin, but the first three 9-mL fractions had to be recycled through the column for binding of the transferrin to be complete.
To isolate transferrin from serum, we applied 300 p.L of serum to the column and carried out immuno-afilnity chromatography (16), collecting 2-mL fractions in acid-leached tubes. The washing cycle with phosphate-buffered saline was continued up to the 10th fraction and the elution with phosphate citrate buffer was continued up to the 20th fraction. We measured the absorbance at 280 mu of each fraction. As judged by electrophoresis on agarose gel, there was a significant loss of 3-globulin content in the recycled fractions. By immunoturbidimetric analysis with anti-human transferrin, no transferrin was detected in the recycled fractions or the washing cycle, but it was present in the fractions obtained in the dissociation cycle.
Al Estimation by Atomic Absorption Spectrophotometry
To estimate the Al content of serum and ultraffitrates, we used a flameless atomic absorption spectrophotometer (Model 603) fitted with a HGA-76B electrothermal furnace, an AS-i autosampler, and a Model 56 potentiometric recorder (all from Perkin-Elmer Ltd., Beaconsfield, Bucks., U.K.). Both serum samples and ultrafiltrates were diluted with an equal volume of dilute Triton X-100 surfactant ("scintillation" grade, BDH). Al was determined in serum as described by Parkinson et al. (17) . The Al content of the ultrafiltrate was determined by using an aqueous Al standard curve (the standard curve constructed by use of standard added to ultrafiltrate paralleled the standard curve for aqueous Al). The detection limit in the ultrafiltrate-i.e., the concentration of Al that gave an absorbance signal equal to twice the standard deviation of the background signal given by a reagent blank-was 2.2 jzg of Al per liter. We assessed the intra-batch precision of Al analysis (CV) by analyzing a pool of ultrafiltrate 11 times on one day; results varied by 7.1%.
Repeating
this procedure on two consecutive days gave results that varied by 5.1%.
We also used flameless atomic absorption spectrophotometry to determine the Al content of fractions from the column. We dried 50 uL of each fraction at 120 #{176}C for 30s with 4.4 #{176}C/s ramp, charred at 1500 #{176}C for 20s with a 80#{176}C/s ramp, and atomized at 2700#{176}C for 6s. Given the low protein content of each fraction, no sample pre-treatment with surfactant was needed. The absorbance signal was recorded in peak-height mode, and the purge gas was set to "miniflow" (50 mL/min). Matrix-matched standards were necessary to determine the Al content of the fractions. Background correction was needed for the fractions from the affinity columns but not for those from the gel-ifitration columns. The detection limit, defined as above, was 0.3 zg of Al per liter.
Subjects
Thirty healthy individuals (ii men and 19 women), ages from 22 to 60 years, and 30 patients with chronic renal failure (22 men and eight women), ages from 28 to 63 years, were studied. The patients with chronic renal failure were being treated by regular hemodialysis against fluid containing57 ± 10 gofAlperliterthreetimesweeklyfor3to5h. They were also being treated with oral Al containing phosphate binders. (mean 30, SD 16 j.tg/L) . The nonultrafiltrable Al ranged from 13 to 175 jig/L (mean 68, SD 40.6 1g/L). In these patients the non-ultrafiltrable component composed 53 to 80% of the total concentration of Al in serum (mean 67%, SD 9%). Figure 1 illustrates the relationship between the ultrafiltrable and non-ultrafiltrable Al and the total serum Al. As the total concentration of serum Al increases, the contribution of the non-ultraflitrable Al clearly becomes increasingly important.
#{149} Ultrafiltrable Al

A Non ultrafiltrable Al
Gel Filtration
In preliminary studies, the Al content of the eluting buffer after it had passed through the column was slightly but consistently less than before (mean 1 &g/L, n = 25), which suggests that the column adsorbed Al from the buffer. We confirmed this by applying 2 mL of a 10 mg/L desferrioxamine solution to the column. This sample contained only 2 ng of Al; after gel ifitration, however, it was found to contain 374 ng of Al. Moreover, when 2 mL of serum (containing 186 ng of Al) from a patient with chronic renal failure was applied to the column, 490 ng of Al was found in the fractions containing transferrin.
Serum, therefore, seems tohave the same capacity for taking up Al from the column that desferrioxamine has.
Serum samples from five healthy volunteers (two men, three women; ages 23 to 53 years) and from 15 patients with chronic renal failure maintained by hemodialysis (nine men, six women; ages 28 to 68 years) were examined by gel filtration. In all subjects, the Al was eluted as a single peak, coincident with transferrin ( Figure 2 ). More Al was recovered with the transferrin than was applied to the column in the serum sample. This additional Al ranged from 90 to 167 ng/mL of serum (mean 134 ng/mL) in healthy subjects and from 40 to 191 ng/mL of serum (mean 106 ng/mL) in patients with chronic renal failure.
We also examined, by gel filtration, serum sampled from five patients with chronic renal failure, 48 h after infusion of 2 g of desferrioxamine. The Al was eluted in two peaks, one with the transferrin as before and the other in the same position as a desferrioxamine-Al marker. Measurement of the Al recovery after gel ifitration showed that, during passage through the column, transferrin adsorbed an average of 145 ng of Al and desferrioxaniine an average of 158 ng of Al.
When we gel-ifitered 2-mL samples containing 2. 
Immuno-Affinity Chromatography
Sera of five chronic renal-failure patients (three men, two women; ages 39 to 62 years) being treated by hemodialysis were studied by affinity chromatography.
The pre-dialysis serum Al concentrations varied from 92 to 155 pg/L (mean 122 pg/L). Of the Al in serum, 35% was eluted in the washing cycle; 65% was recovered in the dissociation cycle with the transferrin (Figure 3) . The Al recovery from the affinity chromatography separations ranged from 97 to 107%, with a mean of 103% (Table 1) .
Discussion
The ultrafIltration method described above separated the serum Al into ultrafiltrable and non-ultrafiltrable fractions. We assumed that the non-ultraflltrable Al was protein bound. Because the ultrafiltration was carried out shortly after the serum was separated from the blood cells and the filtration cell was kept under pressure with CO2/air, dissociation of the protein-bound Al because of changes in pH is unlikely. Furthermore, the method gave the same result when compared with direct ultrafiltration through the hemodialyzer during hemodialysis, which suggests that the results represent the in vivo protein binding of Al in serum. The method obviates Al contamination, recovery is almost complete, and the reproducibility is good.
The mean (± SD) proportion of ultrafiltrable serum Al in normal subjects was 46% (±7.4%), close to the value of 41% reported by Lundin et al. 
Wilting cyds
Al leg/LI Our affinity-chromatography findings confirm that most of the serum Al is bound to transferrin.
The Al eluted in the washing cycle (35%) is probably the ultrafiltrable portion of the serum Al (33% of the serum Al of patients with chronic renal failure is ultrafiltrable).
Because the Al recovery in the affinity chromatography is complete (103%), the column packing does not seem to adsorb the "unbound" Al and should be useful for further quantitative studies. We therefore conclude that transferrin is the major Albinding protein in both normal subjects and patients with chronic renal failure, in agreement with the findings of Trapp 
